MEDI0639
MEDI0639 (21H3RK) is a human monoclonal antibody (mAb) targeting DLL4. MEDI0639 inhibits Notch1 binding to Dll4. MEDI0639 reverses Notch1-mediated growth inhibition of human umbilical vein endothelial cells in vitro. MEDI0639 promotes human angiogenesis and reduces the number of vessels covered by smooth muscle actin-positive mural cells. MEDI0639 can be used in Small cell lung cancer and solid tumors research[1].
Product Specifications
Product Name Alternative
21H3RK
UNSPSC
12352203
Target
Notch
Related Pathways
Neuronal Signaling; Stem Cell/Wnt
Applications
Cancer-programmed cell death
Field of Research
Cancer
Purity
98.78
Smiles
[MEDI0639]
References & Citations
[1]Jenkins DW, et al. MEDI0639: a novel therapeutic antibody targeting Dll4 modulates endothelial cell function and angiogenesis in vivo. Mol Cancer Ther. 2012 Aug;11 (8) :1650-60.
Shipping Conditions
Dry Ice
Storage Conditions
-80°C
Scientific Category
Inhibitory Antibodies
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
ARO-A17369-01 50 µg
Anti-Thermus thermophilus SecY Antibody (ABS0321)
Sign In for Pricing
View Details ARO-A17369-02 100 µg
Anti-Thermus thermophilus SecY Antibody (ABS0321)
Sign In for Pricing
View Details